Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Osteosarcoma 29Dendritic Cell Sarcoma, Interdigitating 25Lymphoma 20Burkitt Lymphoma 20Lymphoma, Large B-Cell, Diffuse 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, Non-Hodgkin 16Leukemia 16Lymphoma, Large-Cell, Immunoblastic 15Lymphoma, Follicular 14Sarcoma 13Recurrence 13Multiple Myeloma 13Leukemia, Myeloid, Acute 13Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Mantle-Cell 12Lymphoma, B-Cell, Marginal Zone 12Hodgkin Disease 12Neoplasms, Plasma Cell 11Myelodysplastic Syndromes 11Leukemia, Myeloid, Accelerated Phase 11Myeloproliferative Disorders 10Leukemia, Myelomonocytic, Chronic 10Congenital Abnormalities 10Leukemia, Myelomonocytic, Juvenile 9Leukemia, Myeloid, Chronic-Phase 9Blast Crisis 9Sezary Syndrome 8Primary Myelofibrosis 8Mycosis Fungoides 8

Interventions

sodium thiosulfate 1Restraint, Physical 1Pantoprazole 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ototoxicity × Methotrexate × Sarcoma × Clear all
NCT01848457 2020-03-16

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Children's Hospital of Philadelphia

Phase 2 Completed
13 enrolled 15 charts
Sarcoma

Ototoxicity, Neoplasms, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡